HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.
复制标题
DOI：
10.1186/bcr3402
复制
发表时间：
2013-03-14
期刊：
影响因子：
--
通讯作者：
Quesenberry CP Jr
中科院分区：
文献类型：
--
作者：
Habel LA;Sakoda LC;Achacoso N;Ma XJ;Erlander MG;Sgroi DC;Fehrenbacher L;Greenberg D;Quesenberry CP Jr
研究表明，两基因比率(HOXB13：IL17BR)和五基因(BUB1B、CENPA、NEK2、RACGAP1、RRM2)分子分级指数(MGI)可以预测早期乳腺癌患者的临床预后。在来自社区医院的一组独立的淋巴结阴性乳腺癌患者中，我们评估了从这些基因签名组合而来的两种风险分类器的性能，MGI+HOXB13：IL17BR和乳腺癌指数(BCI)。对1985~1994年间未接受辅助化疗的4964例淋巴结阴性浸润性乳腺癌患者进行了病例对照研究。对于191例(乳腺癌死亡)和417名匹配的对照，可获得存档的肿瘤组织，并通过RT-PCR分析7个感兴趣基因和4个归一化基因的表达水平。使用Logistic回归方法估计与MGI+HOXB13：IL17BR和BCI预先指定的风险类别相关的乳腺癌死亡的相对风险(RR)和10年绝对风险。MGI+HOXB13：IL17BR和BCI都将超过一半的ER阳性患者归类为低风险。根据MGI+HOXB13：IL17BR和3.5%(95%CI 1.9%~5.1%)，ER阳性、三苯氧胺治疗的低、中、高风险组乳腺癌死亡的10年绝对风险分别为3.7%(95%可信区间1.9%~5.4%)、5.9%(95%可信区间3.0%~8.6%)和12.9%(95%可信区间7.9%~17.6%)。BCI为7.0%(95%CI为3.8%~10.1%)和12.9%(95%CI为7.1%~18.3%)。MGI+HOXB13：IL17BR对ER阳性、未经治疗的患者分别为5.7%(95%CI 4.0%~7.4%)、13.8%(95%CI 8.4%~18.9%)、15.2%(95%CI 9.4%~20.5%)和5.1%(95%CI 3.6%~6.6%)、18.6%(95%CI 10.8%~25.7%)，BCI为17.5%(95%CI为11.1%~23.5%)。在调整了肿瘤的大小和分级后，两个分类器的高风险类别和低风险类别的乳腺癌死亡的RRS仍然升高，但对于接受他莫昔芬治疗和未接受治疗的患者来说，RRS有所降低。在未接受辅助化疗的ER阳性、淋巴结阴性的患者中，MGI+HOXB13：IL17BR和BCI与乳腺癌死亡风险相关。两种风险分类器似乎都提供了超出标准预后因素的风险信息。
Studies have shown that a two-gene ratio (HOXB13:IL17BR) and a five-gene (BUB1B, CENPA, NEK2, RACGAP1, RRM2) molecular grade index (MGI) are predictive of clinical outcomes among early-stage breast cancer patients. In an independent population of lymph node-negative breast cancer patients from a community hospital setting, we evaluated the performance of two risk classifiers that have been derived from these gene signatures combined, MGI+HOXB13:IL17BR and the Breast Cancer Index (BCI). A case-control study was conducted among 4,964 Kaiser Permanente patients diagnosed with node-negative invasive breast cancer from 1985 to 1994 who did not receive adjuvant chemotherapy. For 191 cases (breast cancer deaths) and 417 matched controls, archived tumor tissues were available and analyzed for expression levels of the seven genes of interest and four normalization genes by RT-PCR. Logistic regression methods were used to estimate the relative risk (RR) and 10-year absolute risk of breast cancer death associated with prespecified risk categories for MGI+HOXB13:IL17BR and BCI. Both MGI+HOXB13:IL17BR and BCI classified over half of all ER-positive patients as low risk. The 10-year absolute risks of breast cancer death for ER-positive, tamoxifen-treated patients classified in the low-, intermediate-, and high-risk groups were 3.7% (95% confidence interval (CI) 1.9% to 5.4%), 5.9% (95% CI 3.0% to 8.6%), and 12.9% (95% CI 7.9% to 17.6%) by MGI+HOXB13:IL17BR and 3.5% (95% CI 1.9% to 5.1%), 7.0% (95% CI 3.8% to 10.1%), and 12.9% (95% CI 7.1% to 18.3%) by BCI. Those for ER-positive, tamoxifen-untreated patients were 5.7% (95% CI 4.0% to 7.4%), 13.8% (95% CI 8.4% to 18.9%), and 15.2% (95% CI 9.4% to 20.5%) by MGI+HOXB13:IL17BR and 5.1% (95% CI 3.6% to 6.6%), 18.6% (95% CI 10.8% to 25.7%), and 17.5% (95% CI 11.1% to 23.5%) by BCI. After adjusting for tumor size and grade, the RRs of breast cancer death comparing high- versus low-risk categories of both classifiers remained elevated but were attenuated for tamoxifen-treated and tamoxifen-untreated patients. Among ER-positive, lymph node-negative patients not treated with adjuvant chemotherapy, MGI+HOXB13:IL17BR and BCI were associated with risk of breast cancer death. Both risk classifiers appeared to provide risk information beyond standard prognostic factors.
登录
查看更多内容
影响因子：
45.3
作者：
Goldhirsch, A;Glick, JH;Senn, HJ
通讯作者：
Senn, HJ
影响因子：
3.8
作者：
Jerevall, Piiha-Lotta;Brommesson, Sara;Stal, Olle
通讯作者：
Stal, Olle
影响因子：
8.8
作者：
Jerevall, P-L;Ma, X-J;Li, H.;Salunga, R.;Kesty, N. C.;Erlander, M. G.;Sgroi, D. C.;Holmlund, B.;Skoog, L.;Fornander, T.;Nordenskjold, B.;Stal, O.
通讯作者：
Stal, O.
影响因子：
45.3
作者：
Ma, Xiao-Jun;Hilsenbeck, Susan G.;Erlander, Mark G.
通讯作者：
Erlander, Mark G.
DOI：
10.1186/bcr3038
发表时间：
2011-10-14
期刊：
Breast cancer research : BCR
影响因子：
--
作者：
Jankowitz RC;Cooper K;Erlander MG;Ma XJ;Kesty NC;Li H;Chivukula M;Brufsky A
通讯作者：
Brufsky A